 Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces achievement of the Wave 2 milestone associated with the CodeEvolver platform technology transfer and license agreement with Novartis Pharma AG Novartis that was executed in May, 2019. Completion of Wave 2 deliverables confirms that Novartis is now equipped to begin to practice the CodeEvolver platform technology at its designated site. It is terrific to see the continued progress establishing Novartis as our newest CodeEvolver licensing partner, stated John Nicols, Codexis President and CEO. 